Earnings Call · Q1 FY2024·2024-05-06

Q1 24EPS +26.09%·Rev n/aQ4 23EPS -16.67%·Rev n/aQ3 23EPS 0.00%·Rev n/aQ2 23EPS -14.29%·Rev n/a⚠ consensus missing

BIOCRYST PHARMACEUTICALS INC BCRX

John Bluth — Investor Relations or Corporate Communications

Jon Stonehouse — Chief Executive Officer

Charlie Gayer — Chief Commercial Officer

Helen Thackray — Head of Research and Development or R&D Executive

Anthony Doyle — Chief Financial Officer

+18.4%1d on move date+17.4% vs SPY3d+14.6%5d+19.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BCRX calls or request research access.

More BCRX calls Browse calls Request research access